Reparative resynchronization in ischemic heart failure: An emerging strategy

Research output: Contribution to journalReview articlepeer-review


Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.

Original languageEnglish (US)
Pages (from-to)1055-1060
Number of pages6
JournalExpert Opinion on Biological Therapy
Issue number8
StatePublished - Aug 2014


  • Biologics
  • Cardiac resynchronization therapy
  • Clinical trial
  • Dyssynchrony
  • Heart failure
  • Myocardial infarction
  • Regenerative medicine
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Reparative resynchronization in ischemic heart failure: An emerging strategy'. Together they form a unique fingerprint.

Cite this